Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.16 (
calcineurin
)
17,112
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interest has emerged in the therapeutic potential of inhibiting store operated calcium (Ca
2+
) entry (SOCE) for melanoma and other cancers because malignant cells exhibit a strong dependence on Ca
2+
flux for disease progression. We investigated the effects of deleting
Selenoprotein K
(SELENOK) in melanoma since previous work in immune cells showed SELENOK was required for efficient Ca
2+
flux through the endoplasmic reticulum Ca
2+
channel protein, inositol 1,4,5-trisphosphate receptor (IP3R), which is due to the role SELENOK plays in palmitoylating and stabilizing the expression of IP3R. CRISPR/Cas9 was used to generate SELENOK-deficiency in human melanoma cells and this led to reduced Ca
2+
flux and impaired IP3R function, which inhibited cell proliferation, invasion, and migration. Ca
2+
-dependent signaling through
calcineurin
was inhibited with SELENOK-deficiency, and gene array analyses together with evaluation of transcript and protein levels showed altered transcriptional programs that ultimately disrupted stemness and pro-growth properties.
In vivo
investigations were conducted using the Grm1-Tg transgenic mouse strain that develops spontaneous metastatic melanoma, which was crossed with SELENOK
-/-
mice to generate the following littermates: Grm1-Tg/SELENOK
-/-
, Grm1-Tg/SELENOK
-/+
, Grm1-Tg/SELENOK
+/+
. SELENOK-deficiency in Grm1-Tg/SELENOK
-/-
male and female mice inhibited primary tumor growth on tails and ears and reduced metastasis to draining lymph nodes down to levels equivalent to non-tumor control mice. Cancer stem cell pools were also decreased in Grm1-Tg/SELENOK
-/-
mice compared to littermates. These results suggest that melanoma requires SELENOK expression for IP3R dependent maintenance of stemness, tumor growth and metastasic potential, thus revealing a new potential therapeutic target for treating melanoma and possibly other cancers.
...
PMID:Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis. 3011 20